Pipeline Database & Screener

Over 1000 entries in Phase 2, 3 or NDA development of small and mid-cap biotech companies listed on AMEX/NASDAQ.Generally no OTC companies are listed unless the upcoming catalyst is a PDUFA event. LARGE cap companies are also NOT featured in the database

Company SCREENER also available to filter through financial and clinical data.

N.B. The short ratio is the number of shares sold short divided by the average daily volume, also known as the number of ”days to cover”.

Pipeline data are updated at the end of each trading day. Click on the date for the source of the catalyst. Financial data are updated each evening.

Subscribe HERE to ensure you receive your weekly free copy of the BioPharmCatalyst Biotech Watchlist and/or our daily option of Biotech Price Movers and Pipeline Database updates. 

Showing 404 companies
Screener
Sort
Stage
Market Cap
Price
Short ratio
Relative Volume
Price to book
FDA Calendar
Company
Price
Change
Market Cap
Outstanding Shares
Short Ratio
Updated
$29.13
+0  +0%
$N/A
0
0.00
12/21/2016
Tap to view 6 drugs
Drug Indication Stage News
Annexin V-128 Apoptosis Phase 2 Phase 2 initiated September 2016
Annexin V-128 Rheumatoid arthritis and ankylosing spondylitis Phase 1/2 Ongoing
Apoptosis Necrosis Phase 2 Phase 2 initiated September 2016
Lutathera Inoperable progressive midgut NETs CRL PDUFA date under priority review was December 28, 2016. CRL issued December 21, 2016.
Somakit-TATE Neuroendocrine tumor diagnosis Approved Approved June 1 2016
Somakit-TOC Neuroendocrine cancers Positive opinion by EMA released in October 2016.
ABBV
$0.00
0  0%
$
0
0.00
01/16/2017
Tap to view 19 drugs
Drug Indication Stage News
ABT-494 Psoriatic Arthritis Phase 3 Phase 3 trial to commence 2017.
ABT-494 Rheumatoid arthritis Phase 3 Phase 3 trial initiated January 2016.
ABT-494 Crohn’s Disease Phase 2b Phase 2b data due 1H 2017.
ABT-494 Atopic Dermatitis Phase 2b Phase 2b data due 2017.
Elagolix Uterine Fibroids Phase 3 Phase 3 initiated by partner Abbvie in January 2016. Data due 4Q 2017.
Elagolix Endometriosis Phase 3 First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints. NDA Filing due 3Q 2017.
Glecaprevir/Pibrentasvir (G/P) Hepatitis C virus (HCV) PDUFA NDA filing announced December 16, 2017. PDUFA estimate December 15, 2017.
Imbruvica First-line MCL (mantle cell lymphoma) Phase 3 Phase 3 data due 1H 2017.
Imbruvica Second-line Chronic graft-versus-host disease (GVHD) Phase 3 NDA filing due 2017.
Imbruvica Marginal zone lymphoma PDUFA priority review sNDA filing announced September 26, 2017. Assume priority review. PDUFA estimate March 26, 2017.
Risankizumab Crohn’s Disease Phase 3 Phase 3 trial to commence 1H 2017.
Risankizumab Psoriasis Phase 3 Phase 3 data due by the end of 2017.
Risankizumab Psoriatic Arthritis Phase 2b Phase 2b data due 1H 2017.
Rova-T First-line small cell lung cancer (SCLC) maintenance Phase 3 Phase 3 trial to commence 2017.
Rova-T (TRINITY) Third-line Small Cell Lung Cancer Phase 2 Phase 2 pivotal data due 1H 2017.
Venclexta Follicular lymphoma (FL) Phase 3 Phase 3 trial to commence 2017.
Venclexta First-line Diffuse large B-cell lymphoma (DLBCL) Phase 3 Phase 3 trial to commence 2017.
Venclexta (MURANO) Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) Phase 3 Phase 3 data due 2017.
Venetoclax Relapsed or refractory multiple myeloma Phase 3 Phase 3 trial initiated July 2016.
$5.30
+0  +0%
$211.78M
39,959,000
8.51
10/20/2016
Tap to view 2 drugs
Drug Indication Stage News
ABO-101 Recessive dystrophic epidermolysis bullosa (RDEB) Phase 2 Phase 2 enrollment commenced September 2016.
ABO-102 Sanfilippo syndrome type A (MPS IIIA) Phase 1/2 Phase 1/2 enrollment completed August 2016. Update provided October 2016 with more analysis due 1Q 2017.
$2.75
+0  +0%
$24.98M
9,082,000
2.47
11/15/2016
Tap to view 1 drug
Drug Indication Stage News
Gencaro - GENETIC-AF trial Chronic Heart Failure Phase 2b Phase 2b interim analysis due 3Q 2017.
$3.00
+0  +0%
$164.52M
54,841,000
2.73
12/12/2016
Tap to view 2 drugs
$31.77
+0  +0%
$3.85B
121,113,000
12.48
12/20/2016
Tap to view 5 drugs
Drug Indication Stage News
Pimavanserin Adjunctive treatment in patients with negative symptoms of schizophrenia Phase 2 Phase 2 initiated November 2016.
Pimavanserin Adjunctive treatment of schizophrenia Phase 3 Phase 3 initiated November 2016.
Pimavanserin Parkinson’s disease psychosis (PDP) Approved Approved April 29 2016
Pimavanserin Alzheimer’s disease psychosis Phase 2 Phase 2 top-line data released December 20, 2016. Primary endpoint met. Key secondary endpoint missed.
Pimavanserin - SERENE Alzheimer’s disease agitation Phase 2 Phase 2 trial initiated October 2016.
$4.20
+0  +0%
$574.06M
136,680,000
4.26
11/30/2016
Tap to view 2 drugs
Drug Indication Stage News
ACH-4471 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 1 Phase 1 interim data released November 2016. Phase 2 planned.
JNJ-4178 - OMEGA-1 Hepatitis C (HCV) Phase 2b Phase 2b trial initiation announced November 30, 2016.
$13.50
+0.45  +3.45%
$668.83M
49,543,000
3.86
11/18/2016
Tap to view 3 drugs
Drug Indication Stage News
ACI-24 (anti-Abeta vaccine ) Alzheimer’s disease Phase 1/2 Phase 1/2 ongoing. IPO September 23, 2016.
ACI-35 (anti-tau vaccine) Alzheimer’s disease Phase 1b Phase 2 trial to commence 2017. IPO September 23, 2016.
Crenezumab Alzheimer’s disease Phase 3 Phase 3 trial commenced 1Q 2016. Phase 2 trial did not meet co-primary endpoints. IPO September 23, 2016.
$21.40
+0  +0%
$987.22M
46,132,000
8.35
01/10/2017
Tap to view 5 drugs
Drug Indication Stage News
Ampyra Approved Decision on Inter Partes Review (IPR) expected March 2017. Legal event (non-clinical).
CVT-301 OFF episodes of Parkinson’s disease (PD) Phase 3 Phase 3 data due 1Q 2017.
CVT-427 Migraine Phase 2 Phase 2 to be initiated 1H 2017.
Dalfampridine Post stroke deficits Phase 3 Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
Tozadenant Parkinson’s disease (PD) Phase 3 Phase 3 data due 1Q 2018.
$28.70
+0  +0%
$615.10M
21,432,000
2.48
11/15/2016
Tap to view 2 drugs
Drug Indication Stage News
A-101 Seborrheic keratosis (SK) NDA Filing Phase 3 trial met endpoints - November 15, 2016. NDA filing 1Q 2017.
A-101 Common warts (verruca vulgaris) Phase 2 Phase 2 data released August 18, 2016. Endpoints met.
$2.85
+0  +0%
$129.20M
45,333,000
17.76
12/13/2016
Tap to view 3 drugs
Drug Indication Stage News
ARX-04 (SAP302) Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury Phase 3 Phase 3 data released August 15 2016
ARX-04 (SAP303) Moderate-to-severe acute pain following a surgical procedure NDA Filing NDA filing announced December 13, 2016.
Zalviso Post-operative pain following open abdominal surgery and hip or knee replacement surgery Phase 3 CRL Jul 26 2014. Additional clinical trial initiated September 2016.
$1.26
+0  +0%
$13.50M
10,712,000
0.02
11/21/2016
Tap to view 1 drug
Drug Indication Stage News
CaPre (TRIFECTA trial) Hypertriglyceridemia Phase 3 Phase 3 to be initiated by the end of 2017.
$4.53
+0  +0%
$N/A
0
0.00
11/21/2016
Tap to view 5 drugs
Drug Indication Stage News
NY-ESO T-cell therapy Synovial sarcoma - cancer Phase 3 Phase 3 to be initiated 2H 2017.
NY-ESO T-cell therapy Ovarian cancer Phase 1/2 Further trials planned for 2H 2016
NY-ESO T-cell therapy Myxoid round cell liposarcoma (MRCLS) Phase 3 Pivotal trial placed on clinical hold due to non-safety issues. Hold released November 2016. Envisage initiation 4Q 2016 or 1Q 2017
NY-ESO T-cell therapy Myeloma Phase 1/2 Further trials planned for 1H 2017.
NY-ESO T-cell therapy Non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1/2 initiated November 2015. Data are due 2017.
$5.17
+0  +0%
$66.62M
12,886,000
5.54
08/02/2016
Tap to view 1 drug
Drug Indication Stage News
RI-002 Primary Immune Deficiency Diseases CRL CRL issued July 29 2016. Third-party manufacturing issues cited.
$3.20
+0  +0%
$69.07M
21,584,000
11.67
12/16/2016
Tap to view 3 drugs
Drug Indication Stage News
APC-1000 Asthma/COPD Phase 2 Phase 3 planned
APC-3000 Allergic Rhinitis Phase 2 Phase 3 IND to be submitted 1H 2017.
Epinephrine Pre-filled Syringe (PFS) Emergency treatment of anaphylaxis. NDA Filing CRL issued March 27 2015. CRL issued again June 6, 2016. NDA resubmission announced December 16, 2016.
$17.13
+0  +0%
$376.55M
21,982,000
29.71
01/09/2017
Tap to view 3 drugs
Drug Indication Stage News
ADS-5102 Multiple sclerosis (MS) Phase 2 Phase 2 data released early June 2016. Evaluating Phase 3 pathway.
ADS-5102 Levodopa-Induced Dyskinesia PDUFA PDUFA date August 24, 2017.
Namzaric Moderate to severe dementia of the Alzheimer’s type. Approved Approved Dec 24 2014
$12.30
+0  +0%
$826.34M
67,182,000
28.43
01/10/2017
Tap to view 4 drugs
Drug Indication Stage News
CRS-207 Mesothelioma - cancer Phase 2 Phase 2 trial to be initiated 1H 2017.
CRS-207 and GVAX Pancreas - ECLIPSE trial Pancreatic cancer Phase 2b Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial Pancreatic cancer Phase 2b Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
Epacadostat and CRS-207 - SEASCAPE Ovarian cancer Phase 1/2 Phase 1/2 dosing initiated March 2016.Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
$3.15
+0  +0%
$131.41M
41,718,000
2.93
11/09/2016
Tap to view 2 drugs
Drug Indication Stage News
ADVM-043 Alpha-1 Antitrypsin (A1AT) Deficiency Phase 1/2 Phase 1/2 trial to be initiated 4Q 2017.
AVA-101 Wet age-related macular degeneration (Wet-AMD) Phase 2a Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
$9.23
+0  +0%
$370.56M
40,147,000
15.76
01/10/2017
Tap to view 7 drugs
Drug Indication Stage News
ADXS-HER2 HER2-driven malignancies - cancer Phase 1b Phase 1b ongoing.
ADXS-PSA and Keytruda Castrate-resistant prostate cancer Phase 1/2 Completed the first two dose-escalation cohorts and launched the third dose-escalation cohort in April 2016. Part B combination portion of trial commenced October 2016. Enrollment to be completed by end of 2017.
Axalimogene filolisbac Cervical cancer Phase 3 Phase 3 trial to be initiated 2H 2017.
Axalimogene filolisbac Anal cancer (FAWCETT) Phase 2 Phase 2 initiated June 2016. Preliminary update due 2H 2017.
Axalimogene filolisbac - AIM2CERV Trial High-risk, locally advanced cervical cancer Phase 3 Phase 3 initiation announced October 2016. Enrollment update at ASCO June 2017.
Axalimogene filolisbac - GOG 0265 study Cervical cancer Phase 2 Phase 2 top-line data released October 24, 2016. Second stage was not completed due to the clinical hold in 2015.
Axalimogene filolisbac + durvalumab Recurrent or refractory HPV-associated cervical cancer and head & neck cancer Phase 1/2 Phase 1/2 updated data due 2H 2017.
$0.00
+0  +0%
$N/A
0
0.00
09/11/2016
Tap to view 1 drug
Drug Indication Stage News
Lomitapide Homozygous familial hypercholesterolemia (HoFH) Approved Early approval Dec 24 2012
$2.55
+0  +0%
$29.76M
11,670,000
2.98
01/04/2017
Tap to view 2 drugs
Drug Indication Stage News
Macimorelin Acetate - Macrilen Adult Growth Deficiency Phase 3 Phase 3 data released January 4, 2017 - trial failed.
Zoptrex Endometrial cancer Phase 3 Phase 3 data due 1Q 2017.
$2.00
+0  +0%
$66.42M
33,209,000
9.09
01/11/2017
Tap to view 2 drugs
Drug Indication Stage News
AFM13 Hodgkin Lymphoma - Cancer Phase 1b Phase 1b update 1H 2017.
AFM13 Hodgkin Lymphoma - Cancer Phase 2 Phase 2a trial to be initiated 1Q 2017 with an update due 2H 2017.
$4.09
+0.02  +0.49%
$356.35M
87,126,000
8.08
11/30/2016
Tap to view 2 drugs
Drug Indication Stage News
INCAGN1876 Solid tumors - cancer Phase 1/2 Phase 1/2 trial commenced June 2016
INCAGN1949 Solid tumors - cancer Phase 1/2 Phase 1/2 trial initiation announced November 30, 2016.
$41.55
+0  +0%
$1.75B
42,014,000
6.63
01/10/2017
Tap to view 6 drugs
Drug Indication Stage News
AG-120 IDH1m Relapsed/Refractory AML - cancer NDA Filing NDA filing due by end of 2017.
AG-120 IDH1 mutant positive cholangiocarcinoma - cancer Phase 2 Phase 2 initiated December 2016.
AG-120 and VIDAZA Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer Phase 3 Phase 3 to be initiated 1H 2017
AG-221 Advanced hematologic malignancies with an IDH2 mutation NDA Filing NDA filed December 2016.
AG-221 - IDHENTIFY Refractory Acute myeloid leukemia (AML) - cancer Phase 3 Global Phase 3 study for AG-221 initiated October 2015. Continue to enrol through 2016
AG-348 Pyruvate kinase deficiency Phase 2 Phase 2 first data released at EHA meeting June 2016. Pivotal trial to be initiated mid-2018.
$5.19
+0.01  +0.19%
$69.70M
13,430,000
0.21
11/21/2016
Tap to view 2 drugs
Drug Indication Stage News
AEB1102 Hyperargininaemia and Hematological Malignancies Phase 1 Phase 1 initiation announced July 2016. Enrollment to be completed in 2017.
AEB1102 Arginase I deficiency Phase 1 Phase 1 to initiated 1H 2016. Top-line data due 1H 2017
AGN
$0.00
0  0%
$
0
0.00
01/16/2017
Tap to view 13 drugs
Drug Indication Stage News
ABICIPAR Diabetic macular edema (DME) Phase 3 Phase 3 trial to be initiated in 2017.
ABICIPAR Age-related macular degeneration (AMD) Phase 3 Phase 3 data due 2018.
ABP 215 Biosimilar candidate to Avastin (bevacizumab) PDUFA BLA filed November 15, 2016. PDUFA estimate September 15, 2017.
AVYCAZ (ceftazidime and avibactam) Complicated Urinary Tract Infections (cUTI) PDUFA priority review sNDA acceptance announced October 11, 2016. PDUFA date estimate February 11, 2017 assuming priority review,
Cenicriviroc (CVC) Nonalcoholic steatohepatitis (NASH) Phase 3 Phase 3 to be initiated 2H 2017.
ESMYA (Venus II) Uterine Fibroids Phase 3 Phase 3 data due 1H 2017.
Liletta Prevention of pregnancy PDUFA sNDA accepted January 4, 2017. PDUFA estimate September 4, 2017.
Linzess (linaclotide) Chronic idiopathic constipation (CIC) PDUFA sNDA acceptance announced June 9, 2016. PDUFA estimate February 9, 2017.
Oxymetazoline HCl cream 1.0% Facial Erythema (Redness) Associated with Rosacea PDUFA FDA Acceptance May 24, 2016. PDUFA estimate January 24, 2017.
RAPASTINEL Major depressive disorder (MDD) Phase 3 Phase 3 initiated October 2016. Data due early 2019.
RELAMORELIN Diabetic Gastroparesis Phase 3 Phase 3 to be initiated 2H 2017.
UBROGEPANT ATOGEPANT Prophylaxis (migraine) Phase 3 Phase 3 initiated August 2016. Data due 2018.
UBROGEPANT ATOGEPANT Acute (migraine) Phase 3 Phase 3 initiated July 2016. Data due 2018.
$2.52
+0  +0%
$72.47M
28,757,000
3.69
01/03/2017
Tap to view 1 drug
$9.40
+0.15  +1.62%
$169.69M
18,052,000
3.27
09/13/2016
Tap to view 2 drugs
Drug Indication Stage News
AAV Gene Therapy Achromatopsia Phase 1/2 Phase 1/2 currently enrolling at slower rate than planned
rAAV-hRS1 X-linked retinoschisis (XLRS) Phase 1/2 Phase 1/2 currently enrolling at slower rate than planned
$21.27
+0  +0%
$901.47M
42,382,000
5.86
11/28/2016
Tap to view 1 drug
$17.96
+0  +0%
$493.02M
27,451,000
0.45
12/12/2016
Tap to view 2 drugs
Drug Indication Stage News
Plazomicin - CARE Serious bacterial infections due to carbapenem-resistant Enterobacteriaceae (CRE) NDA Filing Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.
Plazomicin - EPIC trial Complicated urinary tract infections (cUTI) NDA Filing Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.
$9.94
+0  +0%
$181.90M
18,300,000
13.24
11/21/2016
Tap to view 2 drugs
Drug Indication Stage News
Vadadustat - INNO2VATE Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD) Phase 3 Phase 3 initiated August 2016. NDA filing pending positive data due 2019. Estimate data release mid-2019.
Vadadustat - PRO2TECT Non-dialysis patients with anemia related to CKD (NDD-CKD) Phase 3 Phase 3 initiated January 2016. NDA filing pending positive data due 2019. Estimate data release mid-2019.
$19.15
+0.05  +0.26%
$120.49M
6,292,000
0.65
11/21/2016
Tap to view 1 drug
Drug Indication Stage News
A4250 Progressive familial intrahepatic cholestasis (PFIC) Phase 3 Phase 3 planned for 1Q 2017.
$21.35
+0  +0%
$1.07B
50,296,000
9.94
11/28/2016
Tap to view 3 drugs
Drug Indication Stage News
ALD403 Chronic Migraine Phase 2b Phase 2b data released March 2016 met primary and secondary endpoints. 24 week data released July 2016.
ALD403 - PROMISE 1 Frequent episodic migraine Phase 3 Phase 3 PROMISE 1 topline data due 1H 2017.
ALD403 - PROMISE 2 Frequent episodic migraine Phase 3 Phase 3 PROMISE 2 initiation announced November 28, 2016. Data due 1H 2018.
$5.35
+0  +0%
$33.41M
6,245,000
1.14
11/20/2016
Tap to view 4 drugs
Drug Indication Stage News
NS2 Dry eye syndrome Phase 2a Phase 2a to be initiated 1H 2017.
NS2 Allergic conjunctivitis Phase 2 Phase 2/3 trial to begin 1H 2017.
NS2 Noninfectious anterior uveitis Phase 2 Phase 2/3 to begin 1H 2017.
NS2 Sjögren-Larsson Syndrome (SLS) Phase 2 Phase 2 data released August 2016. Phase 3 trial to be initiated 2H 2017.
$1.27
+0  +0%
$82.37M
64,862,000
3.05
09/11/2016
Tap to view 1 drug
Drug Indication Stage News
Iluvien Diabetic macular edema Approved CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
$41.60
+0  +0%
$3.57B
85,813,000
5.52
01/11/2017
Tap to view 9 drugs
Drug Indication Stage News
ALN-CC5 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 1/2 Phase 1/2 initial data presented at ASH 2016.
ALN-GO1 Primary Hyperoxaluria Type 1 (PH1) Phase 1/2 Phase 1/2 initiated March 2016. Initial data released September 2016.
ALN-HBV Chronic hepatitis B virus (HBV) Phase 1/2 Phase 1/2 trial initiated July 2016. Data are due mid 2017
ALN-TTRsc02 ATTR amyloidosis Phase 1 Development plan to be confirmed following APOLLO data release in mid 2017.
Fitusiran Hemophilia Phase 3 Phase 3 program to be initiated early 2017, with initial data due mid-late 2017.
Givosiran Acute hepatic porphyrias Phase 1 Phase 1 additional data due June 2017 with a Phase 3 trial to be initiated in late 2017.
Inclisiran Homozygous Familial Hypercholesterolemia (HoFH) Phase 3 Phase 3 trial initiation announced January 8, 2017.
Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Phase 3 Phase 3 data due mid 2017.
Revusiran ENDEAVOUR ATTR in patients with familial amyloidotic cardiomyopathy (FAC) Phase 3 Phase 3 trial discontinued October 2016.
ALXN
$0.00
0  0%
$
0
0.00
01/16/2017
Tap to view 7 drugs
Drug Indication Stage News
ALXN1007 Gastrointestinal graft-versus-host disease (GI-GvHD) Phase 2 Phase 2 interim data presented at EHA June 2016.
ALXN1101 Molybdenum cofactor deficiency (MoCD) Type A Phase 2/3 Phase 2/3 enrolling.
ALXN1210 atypical Hemolytic Uremic Syndrome (aHUS) Phase 3 Phase 3 enrollment commenced 4Q 2016.
ALXN1210 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 3 Phase 3 enrollment commenced 4Q 2016. Enrollment to be completed 2017.
Eculizumab Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD) Phase 3 Phase 3 data due 2017.
Eculizumab Refractory generalized myasthenia gravis (gMG) NDA Filing NDA filing announced January 9, 2017.
SBC-103 MPS IIIB Phase 1/2 Phase 1/2 ongoing. 6 and 12 month data due 2017.
$23.00
+0  +0%
$786.81M
34,209,000
6.53
01/10/2017
Tap to view 3 drugs
Drug Indication Stage News
Feraheme Adults with iron deficiency anemia (IDA) Phase 3 Phase 3 trial to be completed estimated 1Q 2017. sNDA due mid 2017.
Makena - auto injector Reduce the risk of preterm birth in women with a singleton pregnancy sNDA Filing PK data due 1Q 2017 with sNDA filing to follow in 2Q 2017.
Rekynda Hypoactive sexual desire disorder (HSDD) NDA Filing NDA filing due early 2018.
AMGN
$0.00
0  0%
$
0
0.00
01/16/2017
Tap to view 16 drugs
Drug Indication Stage News
ABP 215 Biosimilar candidate to Avastin (bevacizumab) PDUFA BLA filed November 15, 2016. PDUFA estimate September 15, 2017.
ABP 710 REMICADE biosimilar - rheumatoid arthritis Phase 3 Phase 3 enrolling. Estimate data end of 2018 using clinicaltrials.gov data.
ABP 798 RITUXAN biosimilar - non-Hodgkin lymphoma Phase 3 Phase 3 enrolling. Estimate data 1H 2018 using clinicaltrials.gov data.
ABP 980 Herceptin biosimilar Phase 3 BLA filing due 2017.
BLINCYTO Ph+ R/R ALL Phase 3 BLA filing due 2017.
CHS-1701 Pegfilgrastim biosimilar PDUFA BLA submission announced August 9, 2016. PDUFA date estimate June 9, 2017.
CNP 520 Alzheimer’s Disease Phase 2/3 Phase 2/3 ongoing.
Erenumab Migraine Phase 3 Phase 3 trial met primary endpoint September 2016. BLA filing due 2017
Erenumab AMG 334 Chronic migraine prophylaxis trial Phase 2 Phase 2 positive data released September 2016.
EVENITY (Romosozumab) Osteoporosis PDUFA PDUFA date July 19, 2017.
KYPROLIS (ARROW) Multiple Myeloma Phase 3 Phase 3 trial initiated June 2015. Data due 2017. Estimate data 1H 2017 using clinicaltrials.gov data.
KYPROLIS (ENDEAVOR) Relapsed Multiple Myeloma Phase 3 Phase 3 trial met PFS endpoint - March 2015.
Omecamtiv mecarbil GALACTIC-HF Acute heart failure Phase 3 Phase 3 commencement announced December 1, 2016.
Parsabiv Secondary hyperparathyroidism (SHPT) PDUFA PDUFA date February 9, 2017.
Repatha Cardiovascular disease Phase 3 Phase 3 cardiovascular outcomes study data expected 1Q 2017. ”
XGEVA Skeletal-related event (SRE) prevention Phase 3 BLA planned for 2017.
$17.15
-0.18  -1.04%
$789.29M
46,023,000
8.11
12/27/2016
Tap to view 3 drugs
Drug Indication Stage News
Albuterol DPI Asthma Phase 2b
Naloxone Intranasal Opioid overdose PDUFA PDUFA February 19, 2017.
Primatene Mist (epinephrine inhalation aerosol) Asthma CRL CRL issued December 27, 2016.
$3.02
+0  +0%
$812.93M
269,181,000
2.32
01/06/2017
Tap to view 1 drug
Drug Indication Stage News
Vascepa REDUCE-IT outcomes trial High Triglycerides With Mixed Dyslipidemia Interim analysis announced September 12, 2016 - trial to proceed.Second interim analysis due 3Q 2017. Final data due 2018.
$50.03
+0  +0%
$731.59M
14,623,000
8.32
11/21/2016
Tap to view 2 drugs
Drug Indication Stage News
Cingal Osteoarthritis Phase 3 Additional Phase 3 trial to be initiated by early 2017.
Monovisc Osteoarthritis Approved Approved Feb 2014
$0.67
+0  +0%
$28.17M
41,955,000
2.66
12/27/2016
Tap to view 3 drugs
Drug Indication Stage News
Blisibimod IgA nephropathy Phase 2 Phase 2 primary endpoint not met
Blisibimod Lupus Phase 3 Phase 3 trial did not meet endpoints - November 10, 2016.
Sollpura (liprotamase) Cystic fibrosis who suffer from exocrine pancreatic insufficiency Phase 3 Top-line data released December 27, 2016 - missed primary endpoint. New trial to be initiated 1Q 2017.
$0.51
-0.03  -5.54%
$5.67M
11,120,000
0.61
01/12/2017
Tap to view 1 drug
Drug Indication Stage News
AB-SA01 Chronic rhinosinusitis (CRS) Phase 1 Phase 2 to be initiated 2H 2017.
$1.50
+0  +0%
$11.63M
7,733,000
1.35
01/10/2017
Tap to view 2 drugs
Drug Indication Stage News
RayVa Secondary Raynaud’s Phenomenon Phase 2b Phase 2b planned - seeking partnership
Vitaros Erectile dysfunction NDA Filing NDA resubmission planned for 3Q 2017.
$17.92
+0  +0%
$419.74M
23,423,000
14.94
11/09/2016
Tap to view 3 drugs
Drug Indication Stage News
AQX-1125 FLAGSHIP Chronic obstructive pulmonary disease (COPD) Phase 2 Phase 2 trail failed - July 2015
AQX-1125 KINSHIP Atopic dermatitis (AD) Phase 2 Phase 2 failed to demonstrate efficacy November 2015
AQX-1125 LEADERSHIP Bladder pain syndrome/interstitial cystitis (BPS/IC). Phase 3 Phase 2 trial did not meet endpoints - June 2015 but postive secondary endpoint data - August 2015. Phase 3 trial commenced September 2016. Top-line data due 4Q 2017.
$1.90
+0  +0%
$28.09M
14,786,000
0.41
12/01/2016
Tap to view 1 drug
Drug Indication Stage News
Pulmaquin - ORBIT-3 and ORBIT-4 Non-cystic fibrosis bronchiectasis (non-CF BE). Phase 3 Phase 3 data released December 1, 2016. One of two trials met primary endpoint.
$14.70
+0  +0%
$695.32M
47,301,000
7.99
01/10/2017
Tap to view 4 drugs
Drug Indication Stage News
RDX227675 Hyperkalemia Onset of action trial data due 2Q 2017.
RDX227675 Hyperkalemia Phase 3 Phase 3 trial initiation announced January 3, 2017.
Tenapanor Hyperphosphatemia in end-stage renal disease (ESRD) patients Phase 3 Phase 3 data due 1Q 2017.
Tenapanor Constipation-predominant irritable bowel syndrome (IBS-C) Phase 3 Phase 3 trial initiated October 2015. Second trial initiated December 2015. Data from first trial due mid 2017, with data from second trial due later that year.
$5.40
+0  +0%
$222.73M
41,246,000
19.75
11/19/2016
Tap to view 4 drugs
Drug Indication Stage News
AGS-003 Non-Small Cell Lung Cancer Phase 2 Phase 2 initiated 1Q 2016. Ongoing as of November 2016.
AGS-003 Early stage renal cell carcinoma (RCC) - cancer Phase 2 Phase 2 trial initial data due 1H 2017.
AGS-003 ADAPT Trial Metastatic renal cell carcinoma (mRCC) Phase 3 Phase 3 overall survival analysis due 1H 2017.
AGS-004 HIV Phase 2 Phase 2 second stage commenced dosing July 2016
$23.69
+0  +0%
$4.60B
194,200,000
6.38
01/10/2017
Tap to view 1 drug
Drug Indication Stage News
To be acquired To be acquired by Takeda. Deal to close by the end of February 2017.
$4.37
+0  +0%
$285.92M
65,427,000
6.27
09/15/2016
Tap to view 1 drug
Drug Indication Stage News
YOSPRALA (PA32540/PA8140) Secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers Approved Approval announced September 15, 2016.
$1.42
+0  +0%
$345.50M
243,313,000
6.75
01/06/2017
Tap to view 4 drugs
Drug Indication Stage News
APD334 Ulcerative colitis Phase 2 Phase 2 data due by the end of 2017.
APD371 Pain associated with Crohn’s disease Phase 2 Phase 2 to be initiated 2017 with data due by the end of 2017.
Lorcaserin Smoking cessation Phase 2 Phase 2 initiated March 2014. Data released Nov 2014
Ralinepag Pulmonary Arterial Hypertension Phase 2 Phase 2 data due 3Q 2017.
$1.58
+0  +0%
$112.37M
71,118,000
5.57
11/21/2016
Tap to view 2 drugs
Drug Indication Stage News
ARQ 087 intrahepatic cholangiocarcinoma (iCCA) Phase 1/2 Phase 2 enrollment to be completed soon - as of November 2016.
Tivantinib (ARQ 197) METIV-HCC trial Previously treated Inoperable Hepatocellular Carcinoma cancer Phase 3 Phase 3 SPA agreed upon. Dosage reduced following recommendation from DMC. Top-line data due 1Q 2017.
$10.87
+0  +0%
$1.83B
168,547,000
3.87
01/11/2017
Tap to view 7 drugs
Drug Indication Stage News
ARRY 797 LMNA A/C-related dilated cardiomyopathy (DCM) Phase 2 Phase 2 data presented at the European Society of Cardiology on August 30, 2016. Phase 3 trial to be initiated in 2017.
ARRY-520 (Filanesib) Refractory Multiple Myeloma Cancer Phase 2 Phase 2 interim data due 2016 but no plans to advance program
Binimetinib - COLUMBUS BRAF mutant melanoma cancer Phase 3 Phase 3 data released September 26, 2016 met primary endpoint. NDA filing due 2017. Data from Part 2 portion of trial due mid-2017.
Binimetinib - MILO Recurrent low-grade serous ovarian cancer (LGSOC) Phase 3 Phase 3 trial discontinued April 2016
Binimetinib (NEMO) NRAS melanoma - cancer PDUFA PDUFA date June 30, 2017. Advisory Committee Meeting expected 1H 2017.
Encorafenib and cetuximab - BEACON CRC BRAF-Mutant Colorectal Cancer Phase 3 Phase 3 initiated June 2016. SPA announced September 2016. Enrollment to be completed 2018.
Selumetinib - SELECT-1 Differentiated thyroid cancer Phase 3 Phase 3 trial did not meet its primary endpoint - August 2016
$2.06
+0  +0%
$152.80M
74,173,000
3.34
11/30/2016
Tap to view 3 drugs
Drug Indication Stage News
ARC-520 injection in combination with entecavir or tenofovir Chronic Hepititis B (HBV) Phase 2 Announced that development will be discontinued - November 29, 2016.
ARC-521 Chronic Hepititis B (HBV) Phase 1/2 Announced that development will be discontinued - November 29, 2016.
ARC-AAT Alpha-1 antitrypsin deficiency (AATD) Phase 2 Announced that development will be discontinued - November 29, 2016.
$14.57
+0  +0%
$250.97M
17,225,000
9.59
07/25/2016
Tap to view 1 drug
Drug Indication Stage News
VEN 307 (diltiazem cream) Anal fissures Phase 3 Phase 3 data from second trial did not meet primary endpoint - Feb 2014. Will not pursue future development
$20.86
+0  +0%
$N/A
0
0.00
01/10/2017
Tap to view 1 drug
Drug Indication Stage News
TransCon Growth hormone deficiency in children Phase 3 Phase 3 initiated August 2016. Enrollment to be completed 4Q 2017.
$4.85
+0.3  +6.59%
$225.15M
46,422,000
9.28
11/22/2016
Tap to view 3 drugs
Drug Indication Stage News
AST-OPC1 SCiSTAR Cervical spinal cord injury Phase 1/2 Phase 1/2 six-month data due January 2017. Interim data presented September 14, 2016.
AST-VAC1 Acute myeloid leukemia (AML) Phase 2b Phase 2b planned for 2018.
AST-VAC2 Non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1/2 trial to be initiated 2017.
$1.51
+0  +0%
$129.10M
85,498,000
21.32
11/21/2016
Tap to view 2 drugs
$1.08
+0.09  +9.09%
$60.21M
55,747,000
4.32
11/23/2016
Tap to view 2 drugs
Drug Indication Stage News
Actimab-A Acute Myeloid Leukemia (AML) Phase 2 Phase 2 initiated September 2016. Interim analysis due mid-2017.
Iomab-B Hematopoietic Stem Cells Transplantation Phase 3 Phase 3 initiated June 2016. Data due 1H 2018.
$1.49
+0  +0%
$5.64M
3,787,000
0.67
01/10/2017
Tap to view 1 drug
Drug Indication Stage News
Fulvestrant Cuctal carcinoma in situ(DCIS) - invasive breast cancer Phase 2 Phase 2 enrollment to be completed by August 2017.
$14.80
+0  +0%
$427.13M
28,860,000
16.96
12/12/2016
Tap to view 5 drugs
Drug Indication Stage News
ATA 129 Epstein-Barr virus (EBV-PTLD) after solid organ transplant (SOT) Phase 3 Phase 3 trial planned for 2017. Trial design confirmed.
ATA 129 - MATCH Epstein-Barr virus (EBV-PTLD) after after hematopoietic cell transplant (HCT) Phase 3 Phase 3 trial planned for 2017. Trial design confirmed.
CMV-CTL Refractory CMV Chorioretinitis or Meningoencephalitis Phase 2 Phase 2 data released at ASH 2015. Expects to meet with FDA during 4Q 2016 to discuss further development
EBV-CTL Nasopharyngeal carcinoma (NPC) Phase 2 Phase 2 trial to be initiated 2017.
PINTA 745 Protein-energy wasting Phase 2 Phase 2 endpoint not met December 2015
$2.09
+0  +0%
$324.13M
155,086,000
4.04
12/21/2016
Tap to view 2 drugs
Drug Indication Stage News
OTREXUP Rheumatoid arthritis (RA) Approved Approved Oct 14 2013
VIBEX QuickShot Testosterone deficiency NDA Filing NDA submission announced December 21, 2016.
$2.36
+0  +0%
$93.76M
39,727,000
2.45
11/17/2016
Tap to view 1 drug
$10.01
-0.02  -0.2%
$412.82M
41,241,000
6.68
01/06/2017
Tap to view 4 drugs
Drug Indication Stage News
Akovaz Hypotension Approved Announced approval May 2 2016
Bloxiverz (neostigmine methylsulfate) Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery Approved Approved Jun 3 2013
Micropump Sodium Oxybate Excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy Phase 3 Phase 3 SPA agreed on - October 2016. Initiation of dosing announced December 16, 2016.
VAZCULEP (phenylephrine hydrochloride) Clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia Approved Approved June 30 2014
$0.62
+0  +0%
$46.66M
75,862,000
3.20
11/04/2016
Tap to view 3 drugs
Drug Indication Stage News
Ficlatuzumab EGFR-mutated Non-small cell lung cancer (NSCLC) Phase 2 Announced September 12, 2016 that its Phase 2 trial has been discontinued
TIVO-3 - tivozanib Third line treatment of patients with renal cell cancer Phase 3 CRL June 10 2013. Phase 3 dosing commenced May 2016. Data due 1Q 2018.
Tivozanib + Opdivo Renal cell cancer (RCC) Phase 1/2 Phase 1 initial safety data due 1H 2017.
$1.40
+0  +0%
$54.10M
38,640,000
4.26
01/12/2017
Tap to view 4 drugs
Drug Indication Stage News
BTA074 5% topical gel Condyloma Phase 2 Phase 2 ongoing.
BTA585 Respiratory syncytial virus (RSV) Phase 2a Phase 2a enrollment completed November 2016. Top-line data due during the next few weeks - as of January 9, 2017. No firm date given. Date listed in FDA Calendar is a BPC estimate only as to the latest possible date (i.e. possibly earlier).
Laninamivir Octanoate - IGLOO Adults with symptomatic influenza A or B infection Phase 2 Phase 2 initiated Jun 2013. Topline data did not meet the primary endpoint - July 2014
Vapendavir - SPIRITUS trial Human rhinovirus (HRV) Phase 2b Phase 2b top-line data due February 2017.
$4.14
+0  +0%
$163.99M
39,610,000
4.78
12/08/2016
Tap to view 1 drug
Drug Indication Stage News
ANAVEX 2-73 Mild to moderate Alzheimer’s disease Phase 2a Phase 2a 12-month data released December 8, 2016. Trial is ongoing.
$52.61
-0.76  -1.42%
$1.46B
27,676,000
4.96
01/10/2017
Tap to view 1 drug
Drug Indication Stage News
AVXS-101 Spinal muscular atrophy (SMA) Type 1 Phase 1 Phase 1 ongoing. Data due 1Q 2017. Pivotal trial to be initiated 1H 2017.
$12.96
+0.22  +1.73%
$1.29B
99,161,000
15.90
01/10/2017
Tap to view 4 drugs
Drug Indication Stage News
Intepirdine - HEADWAY-DLB Dementia with Lewy bodies (DLB) Phase 2b Phase 2b data due 4Q 2017
Intepirdine - MINDSET Alzheimer’s disease Phase 3 Phase 3 data are due 3Q 2017.
Nelotanserin DLB patients experiencing REM Behavior Disorder (RBD) Phase 2 Phase 2 data due 2H 2017.
Nelotanserin Visual hallucinations in subjects with Lewy body dementia Phase 2 Phase 2 data due February 2017.
$5.55
+0  +0%
$106.30M
19,153,000
11.73
01/03/2017
Tap to view 5 drugs
Drug Indication Stage News
AXS-02 Complex regional pain syndrome (CRPS) Phase 3 Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 1Q or 2Q 2017.
AXS-02 Chronic Low Back Pain Associated with Modic Changes Phase 3 Phase 3 planned. IND to be filed by end of 2016.
AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions Phase 3 Phase 3 commenced March 2016. Continues to enroll as of November 2016.
AXS-05 Agitation in patients with Alzheimer’s disease (AD) Phase 2/3 Phase 2/3 to be initiated 1H 2017.
AXS-05 STRIDE-1 Treatment resistant depression Phase 3 Phase 3 initiated March 2016. Continues to enroll as of November 2016.
AZN
$0.00
0  0%
$
0
0.00
01/16/2017
Tap to view 26 drugs
Drug Indication Stage News
Acalabrutinib Blood cancer Phase 2 Phase 2 data 1H 2017.
Anifrolumab Lupus Phase 3 Phase 3 data due 2018. Estimate 1H 2018 using clinicaltrials.gov data.
Benralizumab Severe, uncontrolled asthma Phase 3 Guided in November for a regulatory filing by the end of 2016.
Brilinta (THEMIS) Type 2 Diabetes Phase 3 Phase 3 data due 1Q 2018.
Bydureon Type 2 Diabetes Phase 3 Phase 3 Cardiovascular Outcome trial data due 2Q 2018.
Bydureon Autoinjector Phase 3 NDA filing due 1H 2017.
Durvalumab Bladder cancer PDUFA priority review BLA acceptance announced December 9, 2017. PDUFA under priority review. Estimate June 9, 2017.
Durvalumab (PACIFIC) Lung cancer Phase 3 Phase 3 data due 2H 2017.
Durvalumab +/- tremelimumab (ARCTIC) Lung cancer Phase 3 Phase 3 data 1H 2017.
Durvalumab +/- tremelimumab (DANUBE) Bladder cancer Phase 3 Phase 3 data due 2018.
Durvalumab +/- tremelimumab (EAGLE) Head & neck cancer Phase 3 Phase 3 data due 1H 2018.
Durvalumab +/- tremelimumab (KESTREL) Head & neck cancer Phase 3 Phase 3 data due 2H 2017.
Durvalumab +/- tremelimumab (MYSTIC) Lung cancer Phase 3 Phase 3 data 1H 2017.
Durvalumab +/- tremelimumab (NEPTUNE) Lung cancer Phase 3 Phase 3 data due 2018.
Faslodex Breast cancer Phase 3 NDA filing 1H 2017.
Lynparza First-line ovarian cancer Phase 3 Phase 3 data due 2H 2017.
Lynparza Breast cancer Phase 3 Phase 3 data 1H 2017.
Lynparza Second-line ovarian cancer Phase 3 NDA filing due 1H 2017.
Moxetumomab Cancer - leukaemia Phase 3 Phase 3 data due 2H 2017.
PT010 Chronic obstructive pulmonary disease (COPD) Phase 3 Phase 3 data due 2018.
Roxadustat Anaemia Phase 3 Phase 3 data due 2H 2017.
Saxagliptin and dapagliflozin Type-2 diabetes PDUFA IMPORTANT NOTE! Announced in earnings call July 28, 2016 that resubmission was made. No date given. 6-month timeline. PDUFA likely BEFORE January 27, 2017.
Selumetinib Thyroid cancer Phase 3 Phase 3 data due 2018.
Tagrisso First-line lung cancer Phase 3 Phase 3 data due 2H 2017.
Tralokinumab Severe, uncontrolled asthma Phase 3 Phase 3 data due 2H 2017.
ZS-9 Hyperkalaemia PDUFA Class 2 6-month resubmission accepted on 18 October 2016. Estimate February/March 2017 PDUFA date.
$4.63
+0.23  +5.23%
$44.59M
9,631,000
0.53
12/21/2016
Tap to view 1 drug
Drug Indication Stage News
MS1819-SD Exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis (CP) Phase 2 Announced December 21, 2016 that Phase 2 enrollment has commenced. Initial data due 1H 2017.
$2.77
+0  +0%
$51.76M
18,687,000
1.75
12/19/2016
Tap to view 1 drug
Drug Indication Stage News
NurOwn Amytrophic lateral sclerosis (ALS) Phase 3 Phase 2 data released July 2016. Phase 3 trial to be initiated 2Q 2017.
$6.25
+0  +0%
$460.99M
73,758,000
13.23
11/07/2016
Tap to view 3 drugs
Drug Indication Stage News
BCX4161 - OPuS-2 Hereditary angioedema Phase 2b Phase 2b data released February 2016 - primary endpoint not met
BCX7353 - APeX-1 Reduce or eliminate attacks in HAE patients Phase 2 Phase 2 data from Part 1 portion of trial due 1Q 2017.
Peramivir - Study 303 INFLUENZA ACUTE Approved Approved Dec 22 2014
$2.00
+0  +0%
$108.24M
54,118,000
5.67
12/13/2016
Tap to view 3 drugs
Drug Indication Stage News
BEMA Buprenorphine Pain Approved Approved October 26 2015
BEMA Buprenorphine/Naloxone (BNX) - BUNAVAIL Opioid dependence Approved Approved June 7 2014
Clonidine gel Painful diabetic neuropathy (PDN) Phase 2b Phase 2b data released December 13, 2016 - primary endpoints not met.
$32.69
+0.84  +2.64%
$1.08B
32,933,000
3.69
12/06/2016
Tap to view 1 drug
Drug Indication Stage News
BGB-3111 Waldenström’s macroglobulinemia Phase 1 Phase 3 trial to be initiated late 2016 or early 2017. Phase 1 updated data presented at ASH 2016.
BIIB
$0.00
0  0%
$
0
0.00
01/16/2017
Tap to view 12 drugs
Drug Indication Stage News
Aducanumab (Aβ mAb) - ENGAGE and EMERGE Alzheimer’s disease Phase 3 Phase 3 enrollment to be completed mid-2018.
BAN2401 (Aβ mAb) Alzheimer’s disease Phase 2 Phase 2 data potentially due late 2017 or 1H 2018.
BG00011 (STX-100) Idiopathic pulmonary fibrosis (IPF) Phase 2 Phase 2 to be completed 2017.
BIIB059 (anti-BDCA2) Lupus Phase 2 Phase 2 dosing commenced October 2016.
BIIB074 (Nav1.7 inhibitor) Trigeminal Neuralgia Phase 3 Phase 3 to be initiated in 2017.
Dapirolizumab pegol (anti-CD40L) Lupus Phase 2 Phase 2 ongoing.
Elenbecestat (E2609) Alzheimer’s disease Phase 3 Phase 3 enrollment commenced October 2016.
Natalizumab (α4-integrin inhibitor) Acute ischemic stroke Phase 2b Phase 2b enrollment to be completed 2017.
Opicinumab (anti-LINGO) Multiple sclerosis (MS) Phase 2b Phase 2b to be initiated 4Q 2017.
Raxatrigine - BIIB074 (Nav1.7 inhibitor) Erythromelagia Phase 2 Phase 2 initiated 2016.
Raxatrigine - BIIB074 (Nav1.7 inhibitor) Lumbosacral Radiculopathy Phase 2 Phase 2 initiated 2016.
XLRS Gene Therapy X-linked retinoschisis (XLRS) Phase 1/2 Phase 1/2 enrolling as of November 2016.
$13.78
+0  +0%
$373.51M
27,105,000
9.09
12/05/2016
Tap to view 4 drugs
Drug Indication Stage News
BPX-401 Hematological cancers that express the CD19 antigen Phase 1/2 Phase 1/2 planned 2H 2016
BPX-501 Adjunct T-cell therapy administered after allogeneic HSCT - (hematopoietic stem cell transplantation) - cancer Phase 1/2 Phase 1/2 update at ASH 2016.
BPX-601 Pancreatic cancer Phase 1/2 Phase 1/2 planned.
BPX-701 PRAME (preferentially-expressed antigen in melanoma) -expressing melanoma, sarcomas and neuroblastoma cancer Phase 1/2 Phase 1/2 planned.
$0.69
+0  +0%
$9.97M
14,506,000
0.06
11/08/2016
Tap to view 3 drugs
Drug Indication Stage News
INOpulse delivery device Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF) Phase 2 Phase 2 initiated May 2016. Data due 1Q 2017.
INOpulse delivery device Pulmonary Arterial Hypertension (PAH) Phase 3 Phase 3 commenced enrolment June 2016. Interim data due 4Q 2017 with top-line data due mid-2018.
INOpulse delivery device Pulmonary Hypertension associated with COPD (PH-COPD) Phase 2 Phase 2 initiated 3Q 2016. Data due 1Q 2017.
$0.91
+0  +0%
$51.07M
56,432,000
0.48
01/10/2017
Tap to view 5 drugs
Drug Indication Stage News
BL-7010 Gluten sensitivity Phase 1/2 Development plans to be released by early 2017.
BL-8040 Consolidation treatment for AML cancer patients Phase 2b Phase 2b initiated August 2015. Interim analysis due in 2018, with top-line results expected in 2019.
BL-8040 Mobilization and collection of bone marrow stem cells Phase 2 Phase 2 trial initiated March 2016. Partial data due 1Q 2017 with top-line results by the end of 2017.
BL-8040 Acute myeloid leukemia (AML) cancer relapsed and refractory Phase 2 Phase 2 data released March 2016. Full set of data presented September 8, 2016
BL-8040 in combination with KEYTRUDA Pancreatic cancer Phase 2 Phase 2 initiated September 2016. Partial data due 2H 2017. Full data due 2H 2018.
$66.75
+0  +0%
$2.49B
37,303,000
4.86
01/10/2017
Tap to view 5 drugs
Drug Indication Stage News
bb2121 Relapsed/refractory multiple myeloma Phase 1 Phase 1 interim data released November 30, 2016 - 78% ORR. Pivotal trial to be initiated 2017.
Lenti-D Childhood cerebral adrenoleukodystrophy (CCALD) Phase 2/3 Phase 2/3 trial initiated October 2013. Interim data released at AAN Conference April 20, 2016.
LentiGlobin β-Thalassemia Phase 1/2 Updated data presented at ASH December 5, 2016.
LentiGlobin - HGB-206 Sickle disease Phase 1/2 Updated data at ASH 2016.
LentiGlobin - HGB-207 Northstar-2 non-β0/β0 transfusion-dependent thalassemia (TDT) Phase 3 Noted on December 14, 2016 that Phase 3 dosing has commenced.
$86.92
+0  +0%
$14.95B
171,987,000
6.13
10/27/2016
Tap to view 7 drugs
Drug Indication Stage News
BMN 270 Hemophilia A Phase 1/2 Phase 1/2 interim data released July 2016. Update due in December 2016. Phase 2b to be initiated 2H 2017.
Cerliponase alfa Batten Disease PDUFA PDUFA date extended by three months to April 27 2017
Kyndrisa Duchenne Muscular Dystrophy (DMD) CRL CRL issued January 14 2016
PEG-PAL Phenylketonuria (PKU) BLA Filing Phase 3 data released March 2016. Primary endpoint hit. Key secondary endpoint missed. NDA (BLA) filing to be filed 1Q 2017.
Reveglucosidase alfa (BMN 701) Pompe Disease Phase 2 Program terminated June 2016
Vimizim (GALNS) (MPS IVA) Morquio A Syndrome Approved Approved Feb 14 2014
Vosoritide Achondroplasia Phase 2 Phase 2 updated data released October 2016. Phase 3 trial to be initiated end of 2016.
BMY
$0.00
0  0%
$
0
0.00
01/16/2017
Tap to view 14 drugs
Drug Indication Stage News
CM-078 – Opdivo Second-line Non-small cell lung cancer (NSCLC) Phase 3 Phase 3 data due 1H 2018.
CM-140 – Opdivo Second-line Non-Hodgkin’s Lymphoma (NHL) Phase 3 Phase 3 data due 1H 2017.
CM-143 – Opdivo Second-line Glioblastoma (GBM) cancer Phase 3 Phase 3 data due 1H 2017.
CM-214 – Opdivo + Yervoy First-line Renal cell carcinoma (RCC) Phase 3 Phase 3 data due 2H 2017.
CM-227 – Opdivo + Yervoy First-line Non-small cell lung cancer (NSCLC) Phase 3 Phase 3 data due 1H 2018.
CM-238 – Opdivo (Adjuvant) Melanoma Phase 3 Phase 3 data due 2H 2018.
CM-331– Opdivo Second-line Small cell lung cancer (SCLC) Phase 3 Phase 3 data due 1H 2018.
CM-451 – Opdivo + Yervoy First-line Small cell lung cancer (SCLC) Phase 3 Phase 3 data due 1H 2018.
CM-459 – Opdivo First-line Hepatocellular carcinoma (HCC) - cancer Phase 3 Phase 3 data due 2H 2017.
CM-511 – Opdivo + Yervoy First-line Melanoma Phase 3 Phase 3 data due 1H 2017.
CM-548 - Opdivo+SOC First-line Glioblastoma (GBM) cancer Phase 2 Phase 2 data due 1H 2018.
CM-602 – Opdivo + Elo + SOC Myeloma Phase 3 Phase 3 data due 2H 2018.
CM-651 – Opdivo + Yervoy First-line Head and Neck Cancer Phase 3 Phase 3 data due 1H 2018.
Opdivo (nivolumab) Bladder cancer PDUFA priority review PDUFA date under priority review March 2, 2017.
$1.85
+0  +0%
$13.55M
7,326,000
1.10
07/25/2016
Tap to view 1 drug
Drug Indication Stage News
TT-034 Hepatitis C Phase 1/2 Announced late February 2016 plans to discontinue development
$0.42
+0.02  +5.5%
$28.58M
67,719,000
0.75
01/04/2017
Tap to view 2 drugs
Drug Indication Stage News
BPX-01 Acne Phase 2b Phase 2b completion of enrollment announced January 4, 2017. Data due 1H 2017.
BPX-03 Moderate to severe periodic breast pain associated with FBC (fibrocystic breast condition) and cyclic mastalgia Phase 3 Phase 3 to be initiated in 2017
$1.07
+0.03  +2.88%
$102.34M
95,645,000
19.70
11/02/2016
Tap to view 1 drug
Drug Indication Stage News
BP-1001 Acute myeloid leukemia (AML) Phase 2 Phase 2 first patient enrolled November 2016.
$53.56
+0  +0%
$382.79M
7,147,000
2.54
11/22/2016
Tap to view 4 drugs
Drug Indication Stage News
XIAFLEX Plantar fibromatosis Phase 2 Endo is currently performing a commercial assessment.
XIAFLEX Human lipomas Phase 2 Phase 2 topline data released June 2016 - endpoints met
XIAFLEX Edematous fibrosclerotic panniculopathy (“cellulite”) Phase 2b Phase 2b data released November 17, 2016. Met endpoints. Phase 3 planned.
XIAFLEX Adhesive Capsulitis (“Frozen Shoulder syndrome”) Phase 2b Phase 2b trial did not meet endpoint. Endo is currently performing a commercial assessment.
$3.46
+0.05  +1.47%
$355.59M
102,772,000
17.34
12/14/2016
Tap to view 4 drugs
Drug Indication Stage News
AST-OPC1 Cervical spinal cord injury Phase 1/2 Phase 1/2 topline data due January 2017.
AST-VAC1 Maintenance of relapse-free-survival in acute myeloid leukemia (AML) Phase 2b Phase 2b planned for 2018.
OpRegen Dry age-related macular degeneration (AMD) Phase 1/2 Phase 2 second cohort underway. Data due early 2017.
Renevia Restoring normal skin contours in for patients with HIV Phase 3 Pivotal trial data due by mid-2017.
$3.71
+0  +0%
$12.53M
3,377,000
8.57
09/22/2016
Tap to view 1 drug
$4.90
+0.3  +6.52%
$101.61M
20,737,000
4.60
11/10/2016
Tap to view 1 drug
Drug Indication Stage News
CB-839 + nivolumab Phase 1/2 Phase 1/2 enrollment commenced August 2016. Initial data due in 2017.
$2.36
-0.04  -1.67%
$31.57M
13,379,000
8.62
01/10/2017
Tap to view 5 drugs
Drug Indication Stage News
CF101 Glaucoma Phase 2 Phase 2 failed to meet endpoint - July 2016
CF101 Rheumatoid arthritis Phase 3 Phase 3 to be initiated in 2017.
CF101 Psoriasis Phase 3 Phase 2/3 trial did not meet primary endpoint late March 2015. Additional Phase 3 planned for 2H 2017.
CF101 Non-alcoholic steatohepatitis (NASH) Phase 2 Phase 2 to be initiated 1Q 2017.
Namodenoson (CF102) Cancer - advanced liver cancer second line Phase 2 Phase 2 enrollment to be completed in mid-2017.
$2.47
+0  +0%
$52.86M
21,399,000
1.47
11/22/2016
Tap to view 3 drugs
Drug Indication Stage News
CAP-1002 ALLSTAR Myocardial infarction (heart attack) Phase 2 Phase 2 enrolling. 6 month data likely due 2Q 2017.
CAP-1002 HOPE-Duchenne Duchenne Muscular Dystrophy (DMD) Phase 1/2 Phase 1/2 enrollment completed September 2016 with data due EARLY 2Q 2017.
Cenderitide Ambulatory heart failure Phase 2 Phase 2 completed. Waiting on data from additional study to determine future
$4.63
+0.07  +1.54%
$104.41M
22,551,000
5.06
01/06/2017
Tap to view 2 drugs
Drug Indication Stage News
(Tucatinib ONT-380) + Herceptin and Xeloda - HER2CLIMB trial HER2+ Metastatic Breast Cancer (MBC) Phase 2 Phase 2 combination trial initiated February 2016. Announced December 7, 2016 that trial size will be increased enabling it to be recognized as a pivotal trial.
(Tucatinib ONT-380) and T-DM1 HER2+ Metastatic Breast Cancer (MBC) Phase 1b Phase 1b updated data presented at SABCS December 9, 2016.
$1.25
+0  +0%
$75.25M
60,196,000
2.34
11/22/2016
Tap to view 3 drugs
Drug Indication Stage News
ENMD-2076 Cancer - Advanced/Metastatic Soft Tissue Sarcoma Phase 2 Phase 2 initiated Jan 2013. Ongoing as of November 2016.
ENMD-2076 Cancer - triple-negative breast cancer Phase 2 Phase 2 initiated Jul 2012. Ongoing as of November 2016.
ENMD-2076 Cancer - fibrolamellar carcinoma (FLC) Phase 2 Phase 2 initiated October 2015. Ongoing as of Nov 2016.
$4.29
+0  +0%
$80.02M
18,652,000
2.34
11/10/2016
Tap to view 2 drugs
Drug Indication Stage News
CAT-1004 Duchenne muscular dystrophy (DMD) Phase 2 Phase 2 data first half of 1Q 2017.
CAT-2054 Hypercholesterolemia Phase 2a Phase 2a did not meet primary endpoint - June 2016
$1.99
+0  +0%
$46.66M
23,447,000
4.32
12/07/2016
Tap to view 2 drugs
Drug Indication Stage News
Arhalofenate Gout Phase 3 Phase 3 planned - partner required.
MBX-8025 Primary biliary cholangitis (PBC) Phase 2 Phase 2 top-line data released late May 2016. Second trial initiation announced December 7, 2016.
$0.65
-0.03  -4.41%
$7.82M
12,026,000
0.09
11/17/2016
Tap to view 2 drugs
Drug Indication Stage News
Factor IX CB 2679d/ISU304 Hemophilia B Phase 1/2 Phase 1/2 trial planned for 1Q 2017.
Marzeptacog alfa Hemophilia Phase 1 Phase 2/3 trial planned for 2017.
$1.55
+0  +0%
$17.03M
10,987,000
0.62
08/15/2016
Tap to view 2 drugs